June 2020 Global Cell Therapy Instrument Market Research Report is Projected to Witness Considerable Growth by 2027BD Bioscience, Danaher (Beckman…

Cell Therapy Instrument market research report covers and analyses several factors which affect the growth of the Cell Therapy Instrument market. The report on the Cell Therapy Instrument market also provides a detailed analysis of the major aspects of the companies such as financial aspects, research and development and the impact of the COVID-19 pandemic on these companies in the estimated forecasts period. [emailprotected] or call us on +1-312-376-8303. Download Report sample for free ckecl here: @ https://www.cognitivemarketresearch.com/machinery-%26-equipment/cell-therapy-instrument-market-report#download_report

Report Scope: Some of the key types analyzed in this report are as follows: Human Cells, Animal Cells

Some of the key applications as follow: Cell Processing, Cell Preservation Distribution & Handling, Process Monitoring & Quality Control

Following are the major key players: BD Bioscience, Danaher (Beckman Coulter Inc.), General Electric, Lonza, Merck Kgaa, Miltenyi Biotec, Sartorius AG, Stemcell Technologies Inc., Terumo Corporation, Thermo Fisher Scientific Inc. Request COVID-19 Impact Analysis for Cell Therapy Instrument by clicking on following links: @ https://www.cognitivemarketresearch.com/machinery-%26-equipment/cell-therapy-instrument-market-report#download_report

The Cell Therapy Instrument market also determines the introduction of new products and strategies which are used by several companies to reduce the impact of the pandemic of COVID-19. The research report also analyses the value chain analysis of the Cell Therapy Instrument market for the estimated forecast period. It also analyses the risk factors which are associated with the Cell Therapy Instrument market.The worldwide geological [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] analysis of the Cell Therapy Instrument market has furthermore been done cautiously in this report.

Inquiry for Buying or Customization of Report: @ https://www.cognitivemarketresearch.com/machinery-%26-equipment/cell-therapy-instrument-market-report#download_report

There are 13 Chapters to display in the Cell Therapy Instrument market: Chapter 1: Introductory overview, Specifications, Classification, and Applications of Cell Therapy Instrument market, Segment by Regions; Chapter 2: Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure; Chapter 3: Technical Data and Manufacturing Plants Analysis of Cell Therapy Instrument, Capacity and Commercial Production Rate, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis; Chapter 4: Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment); Chapter 5: Regional Analysis Chapter 6 and 7: Segment Analysis by Types and Applications Chapter 8: Company profiling of major manufacturers Chapter 9: Market Trend Analysis, Regional Market Trend, Market Trend by Product Type and Applications Chapter 10: Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis; Chapter 11, 12 and 13: Cell Therapy Instrument sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.. To check the complete Table of Content click here: @ https://www.cognitivemarketresearch.com/machinery-%26-equipment/cell-therapy-instrument-market-report#table_of_contents In addition, the report on Cell Therapy Instrument market also provides a detailed analysis of the impact of the several political, environmental, social, technological, legal and economical factors which are likely to affect the Cell Therapy Instrument market. Moreover, the change in the trading policies due to COVID-19 has also been covered in depth.The report also provides a detailed analysis of the financial information, companies which are operating and the key strategies which are used by these players to overcome the impact of the COVID-19 pandemic.

About Us: http://www.cognitivemarketresearch.com/about-us Nicolas Shaw, Sales Manager, Global Business Development, Website: http://www.cognitivemarketresearch.com Email: [emailprotected] or call us on +1-312-376-8303. Address: 20 N State Street, Chicago, Illinois, 60602, United States.

**********Download the Entire Report************************************************* https://www.cognitivemarketresearch.com/machinery-%26-equipment/cell-therapy-instrument-market-report

Read the rest here:
June 2020 Global Cell Therapy Instrument Market Research Report is Projected to Witness Considerable Growth by 2027BD Bioscience, Danaher (Beckman...

Advanced therapy medicinal products regulations in the EU – Regulatory Focus

This article explains some of the terminology relating to advanced therapy medicinal products (ATMPs), including gene and cell-based therapies, tissue-engineered products, and combined ATMPs. The author explains the key EU regulations and guidance documents for each therapy type, and discusses marketing authorization, accelerated regulatory pathways, and market access. He advises companies navigating this complex regulatory environment to engage with the regulatory agencies early and often during the approval process and to seek external regulatory support if in-house resources are limited. Introduction Advanced therapy medicinal products include cell therapies, gene therapies, and tissue- engineered products. These highly complex treatments differ from traditional medicines, both in how they are made and administered, and in the type of benefits they may provide. These are products for which regulations were established fairly recently and that present challenges to the regulatory agencies on how to best to regulate them within the existing regulatory framework. Terminology Gene therapies Genes therapies treat disease by replacing, inactivating, or introducing genes into the body (see Figure 1). They deliver a corrected copy of a faulty or missing gene, typically using a vector or carrier molecule. The new gene allows cells to function correctly, alleviating all, or some, disease symptoms and potentially offering a long-term cure. Gene therapy medicinal product refers to a biologic medicinal product, which has the following characteristics:

Cell-based therapies Cell-based therapies involve transplanting substantially manipulated cells or cellular material into a patient. In some cases, the genetic material in the cells may be genetically modified. Cell therapy restores or alters certain cells to deliver therapy. Cells are modified outside of the body first.

Cells may be from the patient (autologous) or from a donor (allogeneic). Autologous therapies are manufactured using cells taken from a patient, which are then re-administered to the same patient. Therefore, each batch is unique and irreplaceable. Allogenic products are those in which batches are manufactured using material from a single donor and administered to different patients. Somatic cell therapy medicinal product refers to a biological medicinal product, which has the following characteristics:

Guidance documents The European Medicines Agency (EMA) provides several guidance documents and operates a specific help desk email address (advancedtherapeis@ema.europe.com):

FIGURE 3 Marketing authorization pathways for ATMPs Reprinted with permission (Detela & Lodge)32 Market access As of May 2020, 10 ATMPs have been granted marketing authorization in Europe seven gene therapies, one cell therapy, and two tissue-engineered products targeting several diseases in different therapeutic areas. An additional five approved ATMPs were removed from the market for commercial reasons. At the time, marketing authorizations for five gene therapies were pending.38 The high number of approved, but not marketed, products can be explained at least partially by the cost of ATMPs. It is, however, important to note the fundamental differences between conventional therapies and ATMPs (see Table 2).

Outlook Navigating this complex regulatory environment means companies need to engage with the regulatory agencies early and often throughout the approval process. Many of these therapies are developed by scientific institutions and medical research groups with typically limited regulatory resources in-house, so it is advisable to seek external regulatory support. This exciting field, with hundreds of products currently tested in clinical trials,39 should yield many new therapies with enormous benefits. Something to look forward to, particularly in a time of a global pandemic crisis. Abbreviations ATMP, advanced therapy medicinal product; CAT, Committee for Advanced Therapies; CHMP, Committee for Medicinal Products for Human Use; EMA, European Medicines Agency; EU, European Union; GMP, good manufacturing practice; SMEs, small- and medium-sized enterprises. References [All references accessed 16 July 2020]

Originally posted here:
Advanced therapy medicinal products regulations in the EU - Regulatory Focus

Impact of COVID-19 on Osteonecrosis Treatment Market Emerging Growth And Forecast to 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co…

A new business intelligence report released by CMI with title Global Osteonecrosis Treatment Market Research Report 2019-2027 is designed covering micro level of analysis by manufacturers and key business segments. The Global Osteonecrosis Treatment Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through primary and secondary statistics sources and it comprises both qualitative and quantitative detailing. Some of the key players profiled in the study are Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

Whats keeping Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities, Ahead in the Market? Benchmark yourself with the strategic moves and findings recently released by CMI

To learn more about this report, request a samplecopy:https://www.coherentmarketinsights.com/insight/request-sample/1490

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, and Methodology.

Market Overview of Global Osteonecrosis Treatment

If you are involved in the Global Osteonecrosis Treatment industry or aim to be, then this study will provide you inclusive point of view. Its vital you keep your market knowledge up to date segmented by Applications and major players. If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide customization according to your requirement.

This study mainly helps understand which market segments or Region or Country they should focus in coming years to channelize their efforts and investments to maximize growth and profitability. The report presents the market competitive landscape and a consistent in depth analysis of the major vendor/key players in the market.

Furthermore, the years considered for the study are as follows:

Historical year 2014 2018

Base year 2019

Forecast period** 2019 to 2027 [** unless otherwise stated]

**Moreover, it will also include the opportunities available in micro markets for stakeholders to invest, detailed analysis of competitive landscape and product services of key players.

Detailed Segmentation:

By Drug ClassNon-steroidal anti-inflammatory drugs (NSAIDS)Anti-coagulantOther drugsBy Distribution ChannelsHospitals pharmaciesRetail pharmaciesOnline pharmacies

Top Players in the Market are: Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co Ltd. Hospitals, clinics, universities,

(*Note: Other Players can be added per Request)

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

[**NOTE: Enquiry before Buying option enables you to share your queries, in advance to procure the report. Kindly fill the enquiry form, and one of our consultants would get in touch with you to discuss the queries and would address them.]

Else place an Inquire before Purchase Global Osteonecrosis Treatment Market Size, Share, Growth, and Forecast 2027 @https://www.coherentmarketinsights.com/insight/request-customization/1490

Important Features that are under offering & key highlights of the report:

Detailed overview of Osteonecrosis Treatment market

Changing market dynamics of the industry

In-depth market segmentation by Type, Application etc

Historical, current and projected market size in terms of volume and value

Recent industry trends and developments

Competitive landscape of Osteonecrosis Treatment market

Strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards Osteonecrosis Treatment market performance

Market players information to sustain and enhance their footprint

Note: *The Download PDF brochure only consist of Table of Content, Research Framework, and Research Methodology.

Request PDF Research Report Brochure @https://www.coherentmarketinsights.com/insight/request-pdf/1490

Major Highlights of TOC:

Chapter One: Global Osteonecrosis Treatment Market Industry Overview

1.1 Osteonecrosis Treatment Industry

1.1.1 Overview

1.1.2 Products of Major Companies

1.2 Osteonecrosis Treatment Market Segment

1.2.1 Industry Chain

1.2.2 Consumer Distribution

1.3 Price & Cost Overview

Chapter Two: Global Osteonecrosis Treatment Market Demand

2.1 Segment Overview

2.1.1 APPLICATION 1

2.1.2 APPLICATION 2

2.1.3 Other

2.2 Global Osteonecrosis Treatment Market Size by Demand

2.3 Global Osteonecrosis Treatment Market Forecast by Demand

Chapter Three: Global Osteonecrosis Treatment Market by Type

3.1 By Type

3.1.1 TYPE 1

3.1.2 TYPE 2

3.2 Osteonecrosis Treatment Market Size by Type

3.3 Osteonecrosis Treatment Market Forecast by Type

Chapter Four: Major Region of Osteonecrosis Treatment Market

4.1 Global Osteonecrosis Treatment Sales

4.2 Global Osteonecrosis Treatment Revenue & market share

Chapter Five: Major Companies List

Chapter Six: Conclusion

Key questions answered

o Who are the Leading key players and what are their Key Business plans in the Global Osteonecrosis Treatment market?

o What are the key concerns of the five forces analysis of the Global Osteonecrosis Treatment market?

o What are different prospects and threats faced by the dealers in the Global Osteonecrosis Treatment market?

o What are the strengths and weaknesses of the key vendors?

Need a discount?

Request discount for this report @https://www.coherentmarketinsights.com/insight/request-discount/1490

Note: *The discount is offered on the Standard Price of the report.an

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact US

Mr.Shah Phone: US +1-206-701-6702/UK +44-020 8133 4027 [emailprotected]

Go here to read the rest:
Impact of COVID-19 on Osteonecrosis Treatment Market Emerging Growth And Forecast to 2027 | Bone Therapeutics, Enzo Biochem Inc., and K-Stemcell Co...

Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab – BioSpace

SOMERSET, N.J. & BURLINGAME, Calif.--(BUSINESS WIRE)-- Catalent and Humanigen, Inc. (HGEN) (Humanigen) today announced the expansion of their relationship, under which Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigens proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005256/en/

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies and consumer health products. Humanigen is a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys lead therapeutic candidate.

Mayo Clinic recently announced data on the first clinical use of lenzilumab in 12 patients with severe and critical COVID-19 pneumonia, the majority of whom showed rapid recovery and hospital discharge. A Phase 3 study is currently underway evaluating hospitalized COVID-19 patients.

Based on lenzilumabs promising clinical data, we are pleased to expand our relationship with Catalent to solidify our ability to manufacture and supply lenzilumab, commented Cameron Durrant, MD, MBA, Chief Executive Officer of Humanigen. If we are able to secure FDA approvals or Emergency Use Authorization, Catalent Biologics deep expertise and integrated OneBio solution will accelerate our ability to get this therapy to patients that need it most.

Catalent has partnered closely with Humanigen to develop and supply lenzilumab for clinical trials, commented Karen Flynn, President of Catalent Biologics and Chief Commercial Officer. The experience we already have with lenzilumab, and our OneBio integrated offering from development to supply, make Catalent uniquely suited to support Humanigen in the journey to make this promising therapy available to COVID-19 patients as soon as possible following receipt of regulatory approvals.

To date, Catalent Biologics has provided early-stage development and clinical cGMP drug substance manufacturing for lenzilumab at its facility in Madison, Wisconsin to support Humanigens ongoing clinical trials across various disease categories. Under the expanded partnership, Catalent is also providing clinical supply support for Humanigens Phase 3 potential registration study in COVID-19 from its Philadelphia facility.

Lenzilumab was originally manufactured in Catalents Madison facility using Catalent Biologics proprietary GPEx cell line development technology. As part of the expanded partnership, Catalent intends to provide additional drug substance clinical supply for Humanigens clinical trials, Expanded Access Program (EAP), as well as additional late-stage development and clinical and potential commercial drug substance manufacturing and vial filling at its Madison and Bloomington, Indiana, sites.

Catalent Biologics Madison facility provides development and drug substance manufacturing, including GPEx cell line development, process development, process validation, formulation development, and clinical and commercial cGMP manufacturing. Its Bloomington facility has deep expertise in sterile formulation, with drug substance development and manufacturing and drug product fill/finish capacity across liquid and lyophilized vials, prefilled syringes, and cartridges as well as primary and secondary packaging.

Catalents OneBio Suite is an integrated solution for the development, manufacturing, and supply of biologic drugs. Launched in May 2019, the suite of offerings is designed to integrate activities and accelerate timelines, reduce risk and simplify development with a single contract, program manager, and development timeline from cell line development to supply, with harmonized quality systems.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection. The companys immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Additionally, Humanigen and Kite, a Gilead Company, are evaluating lenzilumab in combination with Yescarta (axicabtagene ciloleucel) in patients with relapsed or refractory large B-cell lymphoma in a clinical collaboration. For more information, visit http://www.humanigen.com.

About Catalent Biologics

Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 13 biopharmaceutical drugs using GPEx cell line development technology, and manufactured 35+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is a full-service partner for adeno-associated virus (AAV) vectors and CAR-T immunotherapies, with deep experience in viral vector scale-up and production. Catalent recently acquired MaSTherCell, adding expertise in autologous and allogeneic cell therapy development and manufacturing. Catalent Cell & Gene Therapy has produced 100+ cGMP batches across 70+ clinical and commercial programs. For more information, visit biologics.catalent.com.

About Catalent

Catalent is the leading global provider of advanced delivery technologies, development, manufacturing, and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs over 13,500 people, including over 2,400 scientists and technicians, at more than 40 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.

Humanigens Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200716005256/en/

Visit link:
Humanigen Expands Partnership with Catalent Biologics to Manufacture Investigational COVID-19 Therapeutic Candidate Lenzilumab - BioSpace

Study: Oxygen therapy improves cognitive function in seniors – Mirage News

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, together with Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University announced that, for the first time, in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed, executive function, in addition to the global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15th, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati, Head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center, and an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, and Dr. Amir Hadanny, the Sagol Center for Hyperbaric Medicine and Research, designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT (n=33) or a control period (n=30) for three months. The studys primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal aging population, said Prof. Efrati. In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration.

Over years of research, we have developed an advanced understanding of HBOTs ability to restore brain function. In the past, we have demonstrated HBOTs potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism, explained Dr. Amir Hadanny. This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms.

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. The researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population, Prof. Efrati explained. We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research.

The research group leader, Professor Shai Efrati, who serves as director of The Sagol Center for Hyperbaric Medicine and Research, and is an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientifics Medical Advisory Board.

Continued here:
Study: Oxygen therapy improves cognitive function in seniors - Mirage News

Comparison of Early and Late Transplant-Associated Thrombotic Microangiopathy – Cancer Therapy Advisor

Transplant-associated thrombotic microangiopathy (TA-TMA) is generally regarded as an early complication of hematopoietic stem-cell transplantation (HSCT); however, late TA-TMA appears to be nearly as common as early TA-TMA and both have similarly poor outcomes, according to findings published in the American Journal of Hematology.

In this retrospective study, the investigators aimed to characterize the risk factors and outcomes associated with early and late TA-TMA among patients receiving allogeneic HSCT. The researchers reviewed electronic medical records of adult patients who received allogeneic HSCT at the Mayo Clinic in Rochester, Minnesota, from January 2000 to June 2019. Patients were diagnosed with either early (before or on day 100 post-HSCT) or late (after day 100 post-HSCT) TA-TMA based on laboratory criteria.

Of 1451 HSCT recipients, 84 (5.8%) were diagnosed with TA-TMA at a median of 80 (range, 3-2595) days post-HCST: 45 patients (3.1%) were diagnosed with early TA-TMA at a median of 28 (range, 3-91) days and 39 patients (2.7%) were diagnosed with late TA-TMA at a median of 303 (range, 122-2595) days.

Of evaluated risk factors, patients with early TA-TMA were more likely to have calcineurin-inhibitor toxicity (66.7% vs 30.8%; P <0.001), acute graph-vs-host disease (GVHD; 66.7% vs 28.2%; P <.001), and prior HSCT (28.9% vs 5.1%; P =.005) compared with patients with late TA-TMA. Patients with late TA-TMA were more likely to have chronic GVHD during TMA than those with early TA-TMA (84.6% vs 0.0%; P <.001).

The median follow up was 6 months (range, 0-132). The overall mortality rate was 34.5% at 3 months and 66.7% at the end of follow up. The estimated median overall survival (OS) was 6 months. After 1 year and 3 years, no differences were observed in survival of patients with early and late TA-TMA (1-year, 36.4% vs 48.9%; 3-year, 33.9% vs 32.9%, respectively). The estimated median OS was not reached in patients who had improvement of TA-TMA, whereas in patients with no improvement, it was 2 months (P <.001).

In a multivariate analysis, older age (for every 10 years, hazard ratio [HR], 1.40; 95% CI, 1.00-1.94; P =.049) and bacterial infection (HR, 2.42; 95% CI, 0.98-6.00; P =.056) were positively associated with mortality in the early TA-TMA group. Conversely, switching from calcineurin-inhibitor to mycophenolate mofetil treatment (HR, 0.40; 95% CI, 0.16-0.99; P =.047) and improvement of TMA (HR, 0.08; 95% CI, 0.03-0.25; P <.001) were negatively associated with mortality in the early TMA group. Only 1 independent predictor, improvement of TA-TMA, was associated with a lower risk of death in the late TMA group (HR, 0.05; 95% CI, 0.02-0.19; P <.001).

Limitations of the study included its retrospective design and variable patient management; additionally, some patients may have been undiagnosed or diagnosed later than the onset of TA-TMA.

In conclusion, the characteristics and etiologies of early and late TMA may be different, but outcomes are similarly unfavorable. Future studies are needed to shed light on methods for a timely diagnosis, better definition of triggers of TMA, and to bring more targeted treatment options, concluded the authors.

Disclosures: Some authors have declared affiliations with the pharmaceutical industry. Please refer to the original study for a full list of disclosures.

Reference

Heybeli C, Sridharan M, Alkhateeb HB, et al. Characteristics of late transplantassociated thrombotic microangiopahy (TATMA) in patients who underwent allogeneic hematopoietic stem cell transplantation [published July 2, 2020]. Am J Hematol. doi: 10.1002/ajh.25922

This article originally appeared on Hematology Advisor

Here is the original post:
Comparison of Early and Late Transplant-Associated Thrombotic Microangiopathy - Cancer Therapy Advisor

Global Cancer Stem Cell Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by Cognitive Market…

Global Cancer Stem Cell Market analysis 2015-2027, is a research report that has been compiled by studying and understanding all the factors that impact the market in a positive as well as negative manner. Some of the prime factors taken into consideration are: various rudiments driving the market, future opportunities, restraints, regional analysis, various types & applications, Covid-19 impact analysis and key market players of the Cancer Stem Cell market. nicolas.shaw@cognitivemarketresearch.com or call us on +1-312-376-8303.

Download Report from: https://cognitivemarketresearch.com/medical-devicesconsumables/cancer-stem-cell-market-report

Global Cancer Stem Cell Market: Product analysis: Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis, Others

Global Cancer Stem Cell Market: Application analysis: Stem Cell Based Cancer Therapy, Targeted CSCs

Major Market Players with an in-depth analysis: Thermo Fisher Scientific Inc., AbbVie Inc., Merck KGaA, Bionomics, Lonza, Stemline Therapeutics Inc., Miltenyi Biotec, PromoCell GmbH, MacroGenics Inc., OncoMed Pharmaceuticals Inc., Irvine Scientific, STEMCELL Technologies Inc., Sino Biological Inc., BIOTIME Inc.

The research is presented in such a way that it consists of all the graphical representations, pie charts and various other diagrammatic representations of all the factors that are used for the research. Cancer Stem Cell market research report also provides information on how the industry is anticipated to provide a highly competitive analysis globally, revenues generated by the industry and increased competitiveness and expansions among various market players/companies.

Get A Free Sample of Cancer Stem Cell Market Report: https://cognitivemarketresearch.com/medical-devicesconsumables/cancer-stem-cell-market-report#download_report

The Cancer Stem Cell industry is projected in assembling information regarding dynamic approximations and also listings of a profitable progression rate annually in the expected duration according to a recent & latest study. The latest Coronavirus pandemic impact along with graphical presentations and recovery analysis is included in the Cancer Stem Cell research report. The research report also consists of all the latest innovations, technologies and systems implemented in the Cancer Stem Cell industries.

Various factors with all the necessary limitations, expenditure/cost figures, consumer behaviour, supply chain, government policies and all the information related to the market have been included in the Cancer Stem Cell Market report. The research report also provides light on various companies & their competitors, market size & share, revenue, forecast analysis and all the information regarding the Cancer Stem Cell Market.

Checkout Inquiry for Buying or Customization of Report: https://cognitivemarketresearch.com/medical-devicesconsumables/cancer-stem-cell-market-report#download_report.

Cancer Stem Cell Market research report provides an in-depth analysis of the entire market scenario starting from the basics which is the market introduction till the industry functioning and its position in the market as well as all the projects and latest introductions & implementations of various products. The research study has been assembled by understanding and combining various analysis of regions globally & companies and all necessary graphs and tables that bring the theory into an exact representation through numerical values and standard tables.

The global estimations of the market value, market information/definition, classifications of all the types & applications, overall threats & dips that can be assumed and many other factors which consist the overall market scenario and its happening globally along with the forthcoming years are compiled in the Cancer Stem Cell market research report. Hence this report can serve as a handbook/model for the enterprises/players interested in the Cancer Stem Cell Market as it consists all the information regarding the Cancer Stem Cell market.

Any query? Enquire Here For Discount (COVID-19 Impact Analysis Updated Sample): Click Here> Download Sample Report of Cancer Stem Cell Market Report 2020 (Coronavirus Impact Analysis on Cancer Stem Cell Market)

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19. (*If you have any special requirements, please let us know and we will offer you the report as you want.)

About Us: Cognitive Market Research is one of the finest and most efficient Market Research and Consulting firm. The company strives to provide research studies which include syndicate research, customized research, round the clock assistance service, monthly subscription services, and consulting services to our clients. We focus on making sure that based on our reports, our clients are enabled to make most vital business decisions in easiest and yet effective way. Hence, we are committed to delivering them outcomes from market intelligence studies which are based on relevant and fact-based research across the global market. Contact Us: +1-312-376-8303 Email: nicolas.shaw@cognitivemarketresearch.com Web: https://www.cognitivemarketresearch.com/

**********Download the Entire Report************************************************* https://cognitivemarketresearch.com/medical-devicesconsumables/cancer-stem-cell-market-report

Continue reading here:
Global Cancer Stem Cell Market is Expected to Grow at Moderate Pace by 2027 Post COVID 19 Pandemic, Latest Market Research Report by Cognitive Market...

Anterior Uveitis Treatment Market Huge Demand by 2028 Cole of Duty – Cole of Duty

Global Anterior Uveitis Treatment Market: Overview

According to the recent market research reports, the global anterior uveitis treatment market is expected to witness high growth in the near future, due to rapidly growing cases of anterior uveitis diseases across the globe. Anterior uveitis leads in inflammation in anterior part of the uvea of eye. Optical infections, exposure to toxic chemicals such as pesticides and acids while manufacturing are considered key factors leading to uveitis. Person experiencing anterior uveitis can feel eye redness, ache, floaters, or even loss of vision. To counter these incidences, companies providing solution of anterior uveitis are coming up new solutions. Mostly, corticosteroid eye drops are recommended for individuals suffering from this disease. However, treatment for such diseases mainly includes immunosuppressive agents and corticosteroids.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6028

In this report on the global anterior uveitis treatment market, analysts have ensured covering key influencing factors affecting the growth in the market. Thus, to give holistic insights they have presented information related to divers, restraints, recent development, rules and regulation in major leading regions, and efforts made by the leading players. SWOT and PESTEL analysis are also systematically given in the report. Moreover, competitors insights along with key strategies used by them are also mentioned in the report.

Global Anterior Uveitis Treatment Market: Notable Developments

Companies providing anterior uveitis treatment facilities hold a very strong position in developing and expanding the growth in the global anterior uveitis treatment market. Companies taking substantial steps through research and development activities, and huge investments made to expand their product portfolios that will give them an upper edge against their competitors. mergers and acquisition, partnership, and collaboration are other strategies widely used by the players. some of the leading players analyzed in this report include Santen Pharmaceutical Co., Ltd, Eyegate Pharmaceuticals, Inc., AbbVie Inc., Aldeyra Therapeutics, Inc., Clearside Biomedical, Inc., Sirion Therapeutics, and Aciont Inc.

Global Anterior Uveitis Treatment Market: Drivers and Restraints

Some of the major driving factors augmenting growth in the global anterior uveitis treatment market include:

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6028

Global Anterior Uveitis Treatment Market: Regional Outlook

With the respect to regional growth, in this report key regions covered include North America, Asia Pacific, Europe, the Middle East and Africa, and Latin America. Among these, North America is estimated to hold maximum share in the global market in the coming years due to rising number of cases related to this disease. Presence of large number of key players in the region has further strengthen position of North America in the global anterior uveitis treatment market. Additionally, development of new methods such as stem cell therapy for treating ocular diseases and few others benefited growth of this region.

Asia Pacific on the other hand is projected to contribute significantly in the growth of the global anterior uveitis treatment market. based in some international research studies, countries in Asia Pacific are witnessing Vogt-Koyanagi-Harada disease, sarcoidosis, and Behcets disease commonly, due to which the requirement of anterior uveitis treatment has increased in this region.

The global anterior uveitis treatment market has been segmented as below:

Treatment Type

Get Discount on Latest Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6028

Distribution Channel

Excerpt from:
Anterior Uveitis Treatment Market Huge Demand by 2028 Cole of Duty - Cole of Duty

Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 – 3rd Watch News

Stem Cell Therapy Market is worth USD 11.99 billion in 2016 and is expected to reach USD 60.94 billion by 2022, growing at a CAGR of 31.1% from 2016 to 2022.

The global stem cell therapy market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the stem cell therapy market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325644

KEY BENEFITS OF THE REPORT: Deeper understanding of the strategies adopted by the key players in this market to stay competitive Granular analysis about the growth map of the market during the next five years Comprehensive analysis of the key market players and their market share

KEY PREMIUM INDUSTRY INSIGHTS: The increasing government initiatives and funding from various organizations, the increased spending on research and development, rapid technological advancement in genomics, and the rising awareness about the stem cell therapy are some of the factors fuelling the growth of the stem cell therapy market.

Other factors, such as the robust product pipelines and increasing approval of the new clinical trials are fuelling the growth of the stem cell therapy market further. However, improper infrastructure, insufficient storage systems, and ethical problems are the major restraints for the stem cell therapy market.

MARKET SEGMENTATION: This report analyzes the stem cell therapy market by the following segments:

Stem Cell Therapy Market, by Treatments Allogeneic Stem Cell Therapy Autologous Stem Cell Therapy Stem Cell Therapy Market, by Applications Oncology Central Nervous System Diseases Eye Diseases Musculoskeletal Diseases Wound & Injuries Metabolic Disorders Cardiovascular Disorders Immune System Disorders Stem Cell Therapy Market, by End-users Hospitals Ambulatory Surgical Centers

Request For Full Report:https://www.kennethresearch.com/sample-request-10325644

KEY MARKET PLAYERS: Key players in the stem cell therapy market include:

Vericel Corporation. Stem Cells, Inc. Mesoblast, Ltd. Gamida Cell Osiris Therapeutics, Inc. Chiesi Farmaceutici S.p.A ReNeuron Group, plc

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

View original post here:
Stem Cell Therapy Market Size, Market Share, Leading Players and Forecast to 2022 - 3rd Watch News

Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 – 3rd…

The global Canine Stem Cell Therapy market is forecasted to reach a market value of ~US$ XX Mn/Bn by the end of 2029 registering a CAGR growth of around XX% during the forecast period (2019-2029). The recent market report provides a detailed analysis of the current structure of the Canine Stem Cell Therapy market along with the estimated trajectory of the market over the course of the stipulated timeframe.

The report provides an in-depth assessment of the numerous factors that are anticipated to impact the market dynamics with utmost precision and accuracy. The SWOT and Porters Five Forces Analysis provides a clear picture about the current operations of the various market players operating in the global Canine Stem Cell Therapy market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

The Canine Stem Cell Therapy market report portrays the market share and the application of each of the sub-segments across various verticals.

The Canine Stem Cell Therapy market report explains how the Canine Stem Cell Therapy is being deployed in different sector.

Competitive landscape:

The report ponders over the market scenario in various geographies and highlights the major opportunities, trends, and challenges faced by market players in each region. An in-depth country wise analysis of each major region provides readers a deep understanding of the regional aspects of the market including, the market share, pricing analysis, revenue growth, and more.

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

The market report on the Canine Stem Cell Therapy market addresses some important questions such as:

Crucial data enclosed in the report:

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

View post:
Canine Stem Cell Therapy Market 2019 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2023 - 3rd...